Authors
Latest:
Adjuvant Nivolumab Does Not Provide DFS Advantage in Localized, High-Risk RCCAdjuvant nivolumab monotherapy did not yield a disease-free survival benefit vs placebo in patients with localized renal cell carcinoma.
Latest:
Breaking New Ground in Childhood CancerAccelerating progress in childhood cancer faces three main obstacles: funding, drugs, and family support.
Latest:
Exploring the Nuances of Postoperative Considerations in Pancreatic CancerZyed Nabeel Zafar, MD, MPH, explores the nuances of postoperative considerations in pancreatic cancer treatment.
Latest:
Florez Focuses on Patient-Centered NSCLC Biomarker Testing DiscussionsDr Florez discusses ways that she helps patients with lung cancer understand the importance of biomarker testing.
Latest:
Dr. Koreth on Key Objectives of the EQUATOR Trial in aGVHDJohn Koreth, MBBS, DPhil, discusses the key objectives of the phase 3 EQUATOR trial in acute graft-versus-host disease.
Latest:
Dr Han on the Investigation of Neoadjuvant Therapy Plus a Dendritic Cell Vaccine in HER2+ Breast CancerHeather Han, MD, discusses initial safety and efficacy results from the phase 2 NATASHA trial in patients with early-stage HER2-positive breast cancer.
Latest:
Dr Xu on the Preliminary Efficacy of SHR-A1904 in Gastric/GEJ CancerRuihua Xu, MD, PhD, discusses data from a phase 1 trial investigating the CLDN18.2-targeted antibody-drug conjugate SHR-A1904 in gastric/GEJ cancer.
Latest:
Dr. Saif on Recommendations for Germline Testing in Pancreatic CancerWasif M. Saif, MD, MBBS, discusses recommendations for germline testing in patients with pancreatic cancer.
Latest:
Clinical Updates for the Management of Lung Cancer Brain MetastasesAs improved cancer therapies are helping patients live longer, the safe and effective management of lung cancer brain metastases is coming to the fore.
Latest:
Personalization Is Key to Successful MentorshipLinda Hasunuma, PhD, highlights the importance of empathy and support as it relates to mentorship, as well as advice for establishing a successful fellowship program and communication strategies.
Latest:
Talquetamab-Based Triplet Elicits Deep Responses in R/R MyelomaTalquetamab plus daratumumab yields improved patient outcomes in patients with relapsed/refractory multiple myeloma.
Latest:
Dr Blakely on the Rationale for Investigating Neoadjuvant Osimertinib in EGFR-Mutated NSCLCCollin Blakely, MD, PhD, discusses a phase 2 trial evaluating the use of neoadjuvant osimertinib in patients with surgically resectable EGFR-mutated non-small cell lung cancer, findings from which were presented at the 2023 ASCO Annual Meeting.
Latest:
Relatlimab Plus Nivolumab and Chemo Improves Clinical Benefit in Stage IV NSCLCFindings from the phase 2 RELATIVITY-104 study demonstrates a clinical benefit with the addition of relatlimab to nivolumab and chemotherapy.
Latest:
Dr. Schmidt on the Promise of Bispecific Antibodies in MyelomaTimothy M. Schmidt, MD, discusses the promise of bispecific antibodies in patients with multiple myeloma.
Latest:
Dr Wong on Hypofractionation vs Conventional Fractionation in Breast Cancer PostmastectomyJulia S. Wong, MD, discusses findings from data presented on patient-reported toxicity results from the randomized trial of fractionation following breast reconstruction in patients with breast cancer.
Latest:
Dr. Jackson on VEGF Versus PARP Inhibitors in Recurrent Ovarian CancerAmanda L. Jackson, MD, discusses choosing between VEGF inhibitors and PARP inhibitors in the treatment of patients with recurrent platinum-sensitive ovarian cancer.
Latest:
Dr. Stefanovic on the Emergence of Umbralisib in MZL and Follicular LymphomaAlexandra Stefanovic, MD, discusses the emergence of umbralisib in marginal zone lymphoma and follicular lymphoma.
Latest:
Dr Wang on Testing for Molecular Alterations in Relapsed/Refractory Urothelial CarcinomaJue Wang, MD, discusses how to approach testing for molecular alterations in patients with relapsed or refractory urothelial carcinoma.
Latest:
Clinical Pearls and Impacts to Practice from EHA 2024The panel concludes by offering final thoughts and insights on recent advancements from EHA 2024.
Latest:
Lete-Cel Generates Durable Responses in Synovial Sarcoma and Myoxid/Round Cell LiposarcomaPatients with metastatic myxoid/round cell liposarcoma or synovial sarcoma expressing NY-ESO-1 and HLA achieved an ORR of 42% with lete-cel.
Latest:
Dr. Lai on the Role of Maintenance Therapy and Secondary Cytoreduction in Ovarian CancerTiffany S. Lai, MD, discusses the role of maintenance therapy and secondary cytoreduction in ovarian cancer.
Latest:
Oncology Providers Face Rising Pressures From Payers Over Therapy ChoicesInsurance companies are beginning to indirectly manage prescribing to better manage costs.
Latest:
ASCO GI 2021: MRD Detection With ctDNA From AssaysExpert physicians discuss data presented at the ASCO GI (American Society of Clinical Oncology Gastrointestinal Cancers Symposium) 2021 annual meeting, regarding minimal residual disease (MRD) detection with ctDNA (circulating tumor DNA) from personalized assays in stage II and III patients with colorectal cancer.
Latest:
Experimental Drug Could Spur Immunotherapy Response in Patients With Non–Small Cell Lung CancerResearch led by UT Southwestern scientists suggests that an investigational drug could restore the ability of some non–small cell lung cancers to respond to an immune checkpoint blockade, a therapy that harnesses the immune system to fight malignant tumors.
Latest:
Dr. Nguyen on Managing Mobocertinib-Related GI Toxicities in EGFR Exon 20 Insertion+ NSCLCDanny Nguyen, MD, discusses management strategies for mobocertinib-related gastrointestinal toxicities in EGFR exon 20 insertion–positive non–small cell lung cancer.
Latest:
Zamani on Disparities in Cancer Care Among Patients of Sexual/Gender MinorityShahrzad A. Zamani, discusses the prevalence of cancer disparities in patients with cancer in sexual and gender minority populations.
Latest:
Digital Health and Process Improvements Enhance Community-Based Patient CareA marked reduction in hospitalizations and emergency department visits are key metrics for value-based care programs. Quality improvement processes and electronic patient management systems may give practices a way to fully embrace these programs and remain mindful of cost while ensuring that patients receive high-quality care.
Latest:
Future Directions in Precision Medicine: An Evolving Treatment LandscapeClosing out their discussion on biomarkers and precision medicine in cancer care, key opinion leaders look toward future evolutions in the oncology landscape.
Latest:
Unmet Needs in the Treatment of HR+/HER2- Breast CancerClosing their discussion, the panel shares some remaining unmet needs in the treatment and management of patients with HR+/HER- breast cancer.
